January 22, 2018 9:33 PM ET

Pharmaceuticals

Company Overview of Questcor Pharmaceuticals, Inc.

Company Overview

As of August 14, 2014, Questcor Pharmaceuticals, Inc. was acquired by Mallinckrodt public limited company. Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of autoimmune and inflammatory disorders. The company primarily offers H.P. Acthar Gel, an injectable drug to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; as exacerbation or maintenance therapy in various cases of systemic lupus erythematosus and systemic dermatomyositis; and as adjunctive therapy for short-term administration in psoriatic arthritis, rheumatoid arthritis, and ankylosing spondy...

1300 North Kellogg Drive

Suite D

Anaheim, CA 92807

United States

Founded in 1990

703 Employees

Phone:

714-786-4200

Fax:

714-789-4229

Key Executives for Questcor Pharmaceuticals, Inc.

Questcor Pharmaceuticals, Inc. does not have any Key Executives recorded.

Questcor Pharmaceuticals, Inc. Key Developments

Baylor College of Medicine to Receive $2 Million from Settlement Reached by Texas with Questcor Pharmaceuticals, Inc

Attorney General Ken Paxton announced that the Baylor College of Medicine will receive $2 million from a settlement reached by Texas with Questcor Pharmaceuticals Inc. Baylor College of Medicine will use the $2 million for funding related to innovative pediatric neurological research projects. In January 2017, Texas, the Federal Trade Commission and four other state attorneys general resolved a lawsuit against Questcor alleging it monopolized the market for Acthar, the only adrenocorticotropic hormone (ACTH)-based therapeutic drug sold in the United States. Acthar is used to treat several diseases, including infantile spasms, a disease in which infants suffer from epileptic seizures that can result in severe injury or death. Questcor blocked competition for Acthar by acquiring the U.S. rights for Synacthen Depot, the only other ACTH-based drug sold in the world. Questcor also increased the price of the drug by 85,000%, charging over $34,000 for a vial of the drug that used to cost $40 per vial. The research that demonstrated Acthar was an effective treatment for infantile spasms was conducted by a team lead by Richard Hrachovy at Baylor College of Medicine in the 1970s and 1980s. In addition to paying disgorgement, Questcor must transfer Synacthen to a firm that will have the incentive to develop and market the drug in the U.S.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Questcor Pharmaceuticals, Inc., please visit www.questcor.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.